Abstract:Background Liver targeting drug delivery systems can improve the curative effects and relieve the cytotoxicity of the chemotherapy drugs in the treatment of liver diseases. Nanoparticles carrying therapeutic drugs are currently under hot investigation with great clinical significance. This study was aimed to investigate the different tissue distribution of the adriamycin polybutylcyanoacrylate nanoparticle (ADM-PBCA-NP) in the mice body after an injection via lateral tail vein, and to study the liver targeting effects of ADM-PBCA-NP in different diameters on normal mice liver.Methods One hundred and eighty Kunming mice were randomly divided into 6 groups with 30 mice in each group (5 treatment groups of ADM-PBCA-NP in the different diameter ranges, non-conjugated free adriamycin injection was employed as the control group). A single dose of either conjugated or free adriamycin equaled 2 mg/kg of body weight was delivered via the tail vein. Five mice in each trail were sacrificed at 5, 15, 30 minutes, 1, 5 and 12 hours postinjection, respectively. The adriamycin concentrations in the respectively collected liver, kidney, spleen, heart, lung and plasma were demonstrated using a high performance liquid chromatography with fluorescence detector.Results Compared with the control group, adriamycin was hardly detected in the heart muscle of the treatment groups (P < 0.05). The nanoparticle-conjugated adriamycin was cleaned up quickly from the kidney tissue. The adriamycin concentrations of the mice liver and spleen in the experimental groups were significantly higher than that in the control group, except for the group with the nanoparticles diameters of (22.3 +/- 6.2) nm (P < 0.05). The ADM-PBCA-NP in (101.0 +/- 20.3) nm diameter had the highest liver distribution, and the second highest adriamycin distribution in liver was the group of (143.0 +/- 23.5) nm diameter (P < 0.05). Moreover, adriamycin was released slowly in the liver during the detection period in the experimental groups. ADM-PBCA-NP in (22.3 +/- 6.2) nm diameter was not distributed in the tissue of the liver, kidney, heart, spleen, and lung.Conclusions ADM-PBCA-NP in 100-150 nm diameter range has the best liver targeting with a characteristic of slow medicine release. It also decreases the medicine distribution in the heart, kidney and lung. In the treatment of liver cancer, the polybutylcyanoacrylate, nanoparticles system has a good liver targeting ability, which increases the anticancer activity and markedly decreases the toxicity of adriamycin.

Study on the Targeting of Nanoparticles Loading TK Gene in Mice

Study on in Vivo Distribution of Liver-Targeting Nanopaticles Encapsulating Thymidine Kinase Gene (TK Gene) in Mice

STUDIES OF TARGETING EFFECTS OF LACTOSAMINATED NANOPARTICLE GENE CARRIER ON LIVER

Study on Targeting Distribution of Cisplatin Stealth Nanoparticles in Normal Mice

Exploring the in Vivo Fates of Rgd and Peg Modified Pei/Dna Nanoparticles by Optical Imaging and Optoacoustic Imaging

Study on Tumor Targeting Ability of Neovessel-Targeted PEGylated Liposomes

Liver Targeting and the Delayed Drug Release of the Nanoparticles of Adriamycin Polybutylcyanoacrylate in Mice

Preparation and Characteristics of DNA-nanoparticles Targeting to Hepatocarcinoma Cells.

[Study on the Preparation of TK-gene Nanoparticles and Its Expression].

Study on Body Distribution and Hepatic Targeting Tendency of Galactosyl Adriamycin Bovine Serum Albumin Nanoparticles in Mice by Radioisotope Tracing

Tissue Distribution of Cisplatin-Loaded Magnetic Nanomedicine in Mice

Nanoparticle-based MRI of metastatic human hepatocellular carcinoma: Targeting survivin gene with siRNA in an animal model

Targeted Study of Bufalin-mPEG-PLGA-PLL-cRGD on Colorectal Cancer in Nude Mice

Preliminary study on in vivo degradation and metabolism of ~(32)P-chromic phosphate-poly(L-lactic) acid seeds implanted into experimental mice

Biodistribution of 32P-Chromicphosphate-poly L-lactic Acid Seeds after Implantation in Models and Their Potential Impact on Immune Function

Reversal Multidrug Resistance and Biodistribution of Targeted Nanoparticles Tf-Peg-PLL-PLGA Combined with Daunorubicin and Tetrandrine in Tumor-Bearing Nude Mice

Experimental Study of 32P-CP-PLLA Microparticle on Human Pancreatic Carcinoma in Nude Mice

Biodistribution of Arctigenin-Loaded Nanoparticles Designed for Multimodal Imaging

Investigation Of New 32p-Cp-Plla Microparticle In The Treatment Of Pancreatic Cancer Mice

Effect of PEG-PEI/Fe3O4 Nano-magnetic Fluid-Tk on Targeting Therapy for Implanted Liver Cancer in Nude Mice

Study on Tissue Distribution of Emodin Solid Lipid Nanoparticles in Mice